SEC Form 4 · accession 0001682806-17-000002
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vaughn B Himes
Officer — Chief Technical Officer
Period of report
Mar 31, 2017
Accepted (ET)
Apr 4, 2017 · 5:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 31, 2017 | M | 10,000 | $9.23 | A | 161,283 | D | |
| Common StockF2,F3 | Mar 31, 2017 | S | 10,000 | $62.7527 | D | 151,283 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F4 | $9.23 | Mar 31, 2017 | M | 10,000 | D | — | Apr 30, 2019 | Common Stock | 10,000 | 13,164 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $62.27 to $63.04. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. Includes 272 shares acquired under the Amended & Restated 2000 Employee Stock Purchase Plan on January 31, 2017.
- F4Shares vested at a rate of 25% on 4/1/10 and monthly thereafter until all the shares were fully vested on 4/1/13.